Leerink Sticks with Outperform on Cencora, Flags Durable Growth Despite Near-Term Revenue Miss
Leerink affirmed an Outperform rating on Cencora (COR) and maintained a $410 price target, shifting its valuation basis from roughly 22.5x CY26 earnings to about 20x CY27 earnings. The firm pointed to a roughly 350 basis point beat on U.S. Healthcare AOI, robust revenue growth and a strong one-year stock return as supporting evidence for continued …